Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus

Thrombosis Research

Volumn 86, Issue 6, 1997, Pages 443-451

  Yoshinari, Mototaka ^a   Yamamoto, Misao ^a   Wakisaka, Masanori ^a   Iwase, Masanori ^a   Takano, Kentaro ^a   Fujishima, Masatoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Bezafibrate; Hypercoagulability; Hyperlipidemia; NIDDM

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CREATININE; D DIMER; FIBRINOGEN; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; BLOOD COAGULATION; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN TIME;

EID: 0030829413     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00093-5     Document Type: Article

References (23)

1. GARCIA-FRADE L.J., DE LA CALLE H., ALAVA I., NAVARRO J.L., CREUGHTON L.J., GAFFNEY P.J. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res. 17:1980;261-266.
2. COLWELL J.A. Vascular thrombosis in type II diabetes mellitus. Diabetes. 42:1993;8-11.
3. HUGHES A., MCVERRY B.A., WILKINSON L., GOLDSTONE A.H., LEWIS D., BLOOM A. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol. 69:1983;254-259.
4. MAYNE E.E., BRIDGES J.M., WEAVER J.A. Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitus. Diabetologia. 6:1970;436-440.
5. KNOBL P., SCHEERNTHANER G., SCHNACK C., PIETSCHMANN P., PROIDL S., PRAGER R., VULOVICH T. Haemostatic abnormalitites persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost. 71:1994;692-697.
6. BREDDIN H.K., KRZYWANEK H.J., ALTHOFF P., KIRCHMAYER C.M., ROSAK C., SCHEPPING M., WEICHERT M., ZIEMAN M., SCHOFFLING K., ÜBERLA K. Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Inter Angiol. 5:1986;181-195.
7. KATO H., UCHIDA K. Automated fluorogenic methods for the evaluation of the extrinsic coagulation reactions in human plasma. Thromb Res. 50:1988;77-90.
8. TAKANO K., YAMAGUCHI T., OKADA Y., UCHIDA K., KISIEL W., KATO H. Hypercoagulability in acute ischemic stroke: Analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. Thromb Res. 58:1990;481-491.
9. SCHONFELD G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis. 111:1994;161-174.
10. DECLERCK P.J., ALESSI M-C., VERSTREKEN M., KRUITHOF E.K.O., JUHSN-VAGUE I., COLLEN D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorvent assay. Blood. 71:1988;220-225.
11. CLAUSS A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol. 17:1957;237-246.
12. ELMS M.J., BUNCE I.H., BUNDESEN P.G., RYLATT D.B., WEBBER A.J., MASCI P.P., WHITAKER A.N. Measurement of crosslinked fibrin degradation products-an immunoassay using monoclonal antibodies. Thromb Haemost. 50:1983;591-594.
13. GRANT M.B., FITZGERALD C., GUAY C., LOTTENBERG R. Fibrinolytic capacity following stimulation with desmopressinacetate in patients with diabetes mellitus. Metabolism. 38:1989;901-907.
14. PANAHLOO A., MOHAMED-ALI V., LANE A., GREEN F., HUMPHRIES S.E., YUDKIN J.S. Determinations of plasminogen inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 44:1995;37-42.
15. SCHNEIDER D.J., NORDT T.K., SOBEL B. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes. 42:1993;1-7.
16. GOUGH S.C.L., GRANT P.J. The fibrinolytic system in diabetes mellitus. Diabetic Med. 8:1991;898-905.
17. BRANCHI A., ROVELLINI A., SOMMARIVA D., GUGLIANDORO A.G., FASOLI A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost. 70:1993;241-243.
18. KARIO K., MATSUO T. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis. 103:1993;131-138.
19. WILKES H.C., MEADE T.W., BARZEGAR S., FOLEY A.J., HUGHES L.O., BAUER K.A., ROSENBERG R.D., MILLER G.J. Gemfibrozil reduces plasma prothrombin fragment F1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost. 67:1992;503-506.
20. CERIELLO A., GIACOMELLO R., STEL G., MOTZ E., TABOGA C., TONUTTI L., PIRIS M., FALLETI E., BARTOLI E. Hyperglycemia-induced thrombin formation in diabetes. Diabetes. 44:1995;924-928.
21. KOSYKTH V.A., PODREZ E.A., NOVIKOV D.K., VIKTOROV A.V., DOLRIN A.G., REPIN V.S., SMIRNOV N. Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes. Atherosclerosis. 68:1987;67-76.
22. STEGMEIER, K., STORK, H., LENTZ, F., LEUSHNER, F., LIEDE, V. Pharmacology and mode of action of bezafibrate in animals. Greten H, Lang PD, and Shettler G. (eds): Lipoprotein and coronary heart disease. 76-82, Gerhard Witzstock Publishing House, New York, Baden-Baden, Cologne, 1980.
23. LAZAROW, P.B. Elevation of peroxisomal β oxidation by bezafibrate. Greten H, Lang PD, and Shettler G. (eds): Lipoprotein and coronary heart disease. 96-100, Gerhard Witzstock Publishing House, New York, Baden-Baden, Cologne, 1980.